This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maglio, D.
Right arrow Articles by Nicolau, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maglio, D.
Right arrow Articles by Nicolau, D. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2003, p. 1771-1773, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1771-1773.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister Fluid

Dana Maglio,1 Renli Teng,2 Per T. Thyrum,2 Charles H. Nightingale,3 and David P. Nicolau1,4*

Center for Anti-Infective Research and Development,1 Division of Infectious Diseases,4 Office for Research, Hartford Hospital, Hartford, Connecticut 06102,3 AstraZeneca Pharmaceuticals, Wilmington, Delaware 198032

Received 12 September 2002/ Returned for modification 21 January 2003/ Accepted 10 February 2003

The pharmacokinetic disposition of meropenem, administered at 500 mg every 8 h, in plasma and cantharidin-induced blister fluid is described. Peak meropenem concentrations in blister fluid lagged behind peak meropenem concentrations in plasma, while a lower elimination rate from blister fluid was also noted. The mean penetration of meropenem into blister fluid was 67%. The pharmacokinetic profile of meropenem in blister fluid supports the utility of this dose in the management of skin and soft tissue infections.

* Corresponding author. Mailing address: Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour St., Hartford, CT 06102. Phone: (860) 545-3941. Fax: (860) 545-3992. E-mail: dnicola{at}harthosp.org.

Antimicrobial Agents and Chemotherapy, May 2003, p. 1771-1773, Vol. 47, No. 5
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.5.1771-1773.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sun, H. K., Duchin, K., Nightingale, C. H., Shaw, J.-P., Seroogy, J., Nicolau, D. P. (2006). Tissue Penetration of Telavancin after Intravenous Administration in Healthy Subjects. Antimicrob. Agents Chemother. 50: 788-790 [Abstract] [Full Text]  
  • Sun, H. K., Ong, C. T., Umer, A., Harper, D., Troy, S., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations. Antimicrob. Agents Chemother. 49: 1629-1632 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»